GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Atlantic International Corp (NAS:ATLN) » Definitions » Cash Ratio

ATLN (Atlantic International) Cash Ratio : 0.02 (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Atlantic International Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Atlantic International's Cash Ratio for the quarter that ended in Sep. 2024 was 0.02.

Atlantic International has a Cash Ratio of 0.02. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.

The historical rank and industry rank for Atlantic International's Cash Ratio or its related term are showing as below:

ATLN' s Cash Ratio Range Over the Past 10 Years
Min: 0.01   Med: 1.06   Max: 10.94
Current: 0.02

During the past 7 years, Atlantic International's highest Cash Ratio was 10.94. The lowest was 0.01. And the median was 1.06.

ATLN's Cash Ratio is ranked worse than
97.27% of 220 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.105 vs ATLN: 0.02

Atlantic International Cash Ratio Historical Data

The historical data trend for Atlantic International's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atlantic International Cash Ratio Chart

Atlantic International Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Ratio
Get a 7-Day Free Trial - - 3.89 5.06 1.06

Atlantic International Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.68 1.06 0.66 0.01 0.02

Competitive Comparison of Atlantic International's Cash Ratio

For the Diagnostics & Research subindustry, Atlantic International's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atlantic International's Cash Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Atlantic International's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Atlantic International's Cash Ratio falls into.


;
;

Atlantic International Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Atlantic International's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=2.694/2.531
=1.06

Atlantic International's Cash Ratio for the quarter that ended in Sep. 2024 is calculated as:

Cash Ratio (Q: Sep. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=1.398/81.824
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Atlantic International  (NAS:ATLN) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Atlantic International Cash Ratio Related Terms

Thank you for viewing the detailed overview of Atlantic International's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Atlantic International Business Description

Traded in Other Exchanges
N/A
Address
3 Federal Street, Billerica, MA, USA, 01821
Atlantic International Corp formerly SeqLL Inc is a technology company providing life sciences instrumentation and research services in collaborative partnerships aimed at the development of novel scientific assets and intellectual property across multiple omics fields. The company leverages its expertise with the True Single Molecule Sequencing platform to empower scientists and researchers with improved genetic tools to greater understand the molecular mechanisms of disease that is essential to the continued development of new breakthroughs in genomic medicine, and that hopefully address the critical concerns involved with precision medicine.
Executives
Daniel Robert Jones officer: President, CEO 317 NEW BOSTON STREET, SUITE 210, WOBURN MA 01801
Douglas Patrick Miscoll director 317 NEW BOSTON STREET, SUITE 2010, WOBURN MA 01801
David Pfeffer director 464 IVY AVENUE, HAWORTH NJ 07644
Patrice M. Milos director 317 NEW BOSTON STREET, SUITE 2010, WOBURN MA 01801
Frances P Scally officer: CHIEF FINANCIAL OFFICER 66 MELANIE LANE, SYOSSET NY 11791
John Whitcomb Kennedy officer: CFO, Secretary 166 WINN STREET, WOBURN MA 01801